(Total Views: 596)
Posted On: 12/13/2021 9:25:51 AM
Post# of 153903
If we have good results with 350mg LL we will probably have even better results with 700mg.
Now imagine a new P3 NASH trial with 700mg and with a trial design based on the information/ revelations we had on the NASH P2 trial and the mother load of information from our cancer and COVID trials ...
I think this is a point many do not see or underestimate. Since we have multiple LL trials ongoing, we learn exponential more about MOA of LL in comparison to other pharma companies with their drug.
The next trial will be a tailor-made suit for NASH, like we have with CD16 for COVID.
Now imagine a new P3 NASH trial with 700mg and with a trial design based on the information/ revelations we had on the NASH P2 trial and the mother load of information from our cancer and COVID trials ...
I think this is a point many do not see or underestimate. Since we have multiple LL trials ongoing, we learn exponential more about MOA of LL in comparison to other pharma companies with their drug.
The next trial will be a tailor-made suit for NASH, like we have with CD16 for COVID.
(7)
(0)
